Coronary disease & ACS

Sex differences in trajectories of LDL cholesterol control in chronic coronary syndromes

Eur J Prev CardiolPublished Registry-based cohort study

Main finding · Failure to reach LDL-C target at inclusionResult — go to the resultAdjusted odds ratio 1.47 95% CI 1.38–1.58

Authors' conclusion

Women with CCS were less likely to have LDL-C measurement available at baseline, to receive lipid-lowering drugs and consistently exhibited poorer LDL-C control than men over the 5-year follow-up.

Study context

Population
Patients with chronic coronary syndromes (CCS) in the international CLARIFY registry with low-density lipoprotein cholesterol (LDL-C) measured at baseline21.6% women
Participants
21,925 patients
Exposure
Women vs men
Outcome
Cardiovascular (CV) death or MI
Follow-up
5-year follow-up
Methodological detailsanalysis of the CLARIFY registry, international, 5-year follow-up
  • Analysis of the CLARIFY registry
  • International
  • 5-year follow-up

Main finding

Failure to reach LDL-C target at inclusion · inclusion

Adjusted odds ratio

1.47

95% CI 1.38–1.58

P < 0.001

By group

Women vs Men
aOR 1.47 (95% CI 1.38–1.58); P < 0.001

As reported in the abstract

Disparity persisted across the 5-year follow-up
P < 0.001 for every year

Observational data: associations, not effects.

Further findings

OutcomeWomenMenEstimateP value
Never reaching target LDL-C during follow-up20.7%15.8%aOR 1.44 (95% CI 1.32–1.56)P < 0.001
LDL-C measurement available at baseline (initial cohort of 32,376) · women less likely to have measurementaOR 1.12 (95% CI 1.06–1.18)P < 0.001
CV death or MI by mean LDL-C during follow-up · 5-year follow-upaHR 1.06 (95% CI 1.04–1.07)P < 0.001

Statin use at inclusion

P < 0.001

Original publication

Sex differences in trajectories of LDL cholesterol control in chronic coronary syndromes. Eur J Prev Cardiol. Published 18 August 2026. doi:10.1093/eurjpc/zwag419

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.